AR103844A1 - CHEMICAL COMPOUND - Google Patents

CHEMICAL COMPOUND

Info

Publication number
AR103844A1
AR103844A1 ARP160100564A ARP160100564A AR103844A1 AR 103844 A1 AR103844 A1 AR 103844A1 AR P160100564 A ARP160100564 A AR P160100564A AR P160100564 A ARP160100564 A AR P160100564A AR 103844 A1 AR103844 A1 AR 103844A1
Authority
AR
Argentina
Prior art keywords
compound according
formula
chemical compound
compound
dimethoxypropan
Prior art date
Application number
ARP160100564A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of AR103844A1 publication Critical patent/AR103844A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1) que es 5-[1-(1,3-dimetoxipropan-2-il)-5-(morfolin-4-il)-1H-1,3-benzodiazol-2-ii]-1,3-dimetil-1,2-dihidropiridin-2-ona, de fórmula (1), o una de sus sales. Reivindicación 2: Un compuesto de acuerdo con la reivindicación 1 o una de sus sales farmacéuticamente aceptable. Reivindicación 3: Un compuesto de acuerdo con la reivindicación 1, que está en forma de base libre. Reivindicación 4: Un compuesto de acuerdo con la reivindicación 3, que está en forma de estado sólido cristalino caracterizado por un patrón de difracción de rayos X en forma de polvo que tiene picos de difracción a valores de 2q de 8,2, 8,6, 11,0, 12,5, 13,0, 14,0, 16,3, 17,1, 18,5, 22,0, 23,7 y 26,7 (± 0,10º 2q de error experimental).Claim 1: A compound of formula (1) which is 5- [1- (1,3-dimethoxypropan-2-yl) -5- (morpholin-4-yl) -1H-1,3-benzodiazol-2-ii ] -1,3-dimethyl-1,2-dihydropyridin-2-one, of formula (1), or one of its salts. Claim 2: A compound according to claim 1 or a pharmaceutically acceptable salt thereof. Claim 3: A compound according to claim 1, which is in the form of a free base. Claim 4: A compound according to claim 3, which is in the form of a crystalline solid state characterized by a powder-shaped X-ray diffraction pattern having diffraction peaks at values of 2q of 8.2, 8.6 , 11.0, 12.5, 13.0, 14.0, 16.3, 17.1, 18.5, 22.0, 23.7 and 26.7 (± 0.10º 2q of experimental error) .

ARP160100564A 2015-03-05 2016-03-03 CHEMICAL COMPOUND AR103844A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201503720A GB201503720D0 (en) 2015-03-05 2015-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
AR103844A1 true AR103844A1 (en) 2017-06-07

Family

ID=52998420

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100564A AR103844A1 (en) 2015-03-05 2016-03-03 CHEMICAL COMPOUND

Country Status (5)

Country Link
AR (1) AR103844A1 (en)
GB (1) GB201503720D0 (en)
TW (1) TW201704230A (en)
UY (1) UY36574A (en)
WO (1) WO2016139292A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527340A (en) 2015-08-11 2018-09-20 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
AU2016305515A1 (en) 2015-08-12 2018-03-08 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CN109280046B (en) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 Benzimidazole derivative, preparation method thereof and application thereof in medicine
CN109384784B (en) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 Sulfonamide derivative, preparation method thereof and application thereof in medicine
JP2022534472A (en) * 2019-04-24 2022-08-01 コンバージーン・リミテッド・ライアビリティ・カンパニー Small molecule bromodomain inhibitors and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (en) 2005-12-12 2008-01-30 Glaxo Group Ltd COLLECTOR TO BE USED IN MEDICINAL DISPENSER
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones

Also Published As

Publication number Publication date
TW201704230A (en) 2017-02-01
WO2016139292A1 (en) 2016-09-09
GB201503720D0 (en) 2015-04-22
UY36574A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
AR103844A1 (en) CHEMICAL COMPOUND
BR112015009850A2 (en) heteroaryl substituted pyridyl compounds useful as kinase modulators
ECSP20025899A (en) COMPOUNDS USEFUL TO INHIBIT CDK7
RS54386B1 (en) Antiviral compounds
MA47575A (en) MONOCYCLIC OGA INHIBITOR COMPOUNDS
AR106237A2 (en) HETEROCYCLIC INHIBITORS OF ASPARTIL PROTEASA, ITS PHARMACEUTICALLY ACCEPTABLE SALTS
PE20201444A1 (en) CRYSTALLINE POLYMORPHES FROM THE FREE BASE OF 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-IL) PYRIDIN-3-IL) METOXY) BENZALDEHYDE
CL2017000705A1 (en) New compounds
CR20150418A (en) TETRAHYDROPIRROLOTIAZINE COMPOUNDS
CU20170057A7 (en) DERIVATIVES OF PHENILTRIAZOL REPLACED WITH HYDROXIALQUIL
CL2016000466A1 (en) Compounds derived from substituted 2-amino pyrimidine, inhibitors of bmi-1 pharmaceutical composition and use in the treatment of cancer.
MA46866A (en) A CRYSTALLINE FORM OF A MAGL INHIBITOR
AR085650A1 (en) SOLID FORMS OF 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-IL) -PIPERIDIN-2,6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND USES
AR098870A1 (en) Polymorphic forms of a chlorohydrate salt of (S) -2- (1- (9H-PURIN-6-ILAMINO) PROPIL) -5-FLUORO-3-PHENYLQUINAZOLIN-4 (3H) -ONA
AR103444A1 (en) CRYSTAL FORM OF A BENCIMIDAZOL DERIVATIVE AND A METHOD OF PREPARATION OF THE SAME
AR097866A1 (en) 4-AZAINDOL DERIVATIVES
EA201592268A1 (en) DIHYDROPYRIDINONE INHIBITORS MGAT2
CO2019004978A2 (en) Therapeutic compounds and methods to use them
ES2531159T3 (en) Compounds and methods for cancer treatment
RS54716B1 (en) Heterocyclic compounds and their uses
CU20210023A7 (en) PYRIDINYL 1,2-OXABOROLAN-2-OL PHOSPHODIESTERASE 4 SUBSTITUTE PHENYL INHIBITORS
MX2016017405A (en) 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same.
AR095097A1 (en) PHENOXYETOXI COMPOUNDS
CU20150168A7 (en) 4- (5- (4-CHLOROPHENYL) -2- (2-CYCLOPROPILACETILE) -1,4-DIMETHYL-1H-PIRROL-3-IL) BENCENOSULPHONAMIDE AS A NACHR ALFA 7 MODULATOR
PH12016500134B1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure